JP2025510815A5 - - Google Patents

Info

Publication number
JP2025510815A5
JP2025510815A5 JP2024556630A JP2024556630A JP2025510815A5 JP 2025510815 A5 JP2025510815 A5 JP 2025510815A5 JP 2024556630 A JP2024556630 A JP 2024556630A JP 2024556630 A JP2024556630 A JP 2024556630A JP 2025510815 A5 JP2025510815 A5 JP 2025510815A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556630A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510815A (ja
Filing date
Publication date
Priority claimed from GBGB2204159.4A external-priority patent/GB202204159D0/en
Application filed filed Critical
Publication of JP2025510815A publication Critical patent/JP2025510815A/ja
Publication of JP2025510815A5 publication Critical patent/JP2025510815A5/ja
Pending legal-status Critical Current

Links

JP2024556630A 2022-03-24 2023-03-24 抗par2抗体 Pending JP2025510815A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2204159.4 2022-03-24
GBGB2204159.4A GB202204159D0 (en) 2022-03-24 2022-03-24 Antibodies
PCT/GB2023/050760 WO2023180767A1 (en) 2022-03-24 2023-03-24 Anti-par2 antibodies

Publications (2)

Publication Number Publication Date
JP2025510815A JP2025510815A (ja) 2025-04-15
JP2025510815A5 true JP2025510815A5 (cg-RX-API-DMAC7.html) 2026-03-31

Family

ID=81449405

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556630A Pending JP2025510815A (ja) 2022-03-24 2023-03-24 抗par2抗体

Country Status (10)

Country Link
US (1) US20250313621A1 (cg-RX-API-DMAC7.html)
EP (1) EP4499694A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025510815A (cg-RX-API-DMAC7.html)
KR (1) KR20240161970A (cg-RX-API-DMAC7.html)
CN (1) CN119137152A (cg-RX-API-DMAC7.html)
AU (1) AU2023238937A1 (cg-RX-API-DMAC7.html)
CA (1) CA3246035A1 (cg-RX-API-DMAC7.html)
GB (1) GB202204159D0 (cg-RX-API-DMAC7.html)
IL (1) IL315704A (cg-RX-API-DMAC7.html)
WO (1) WO2023180767A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121693517A (zh) * 2023-04-14 2026-03-17 泰维尼生物公司 双重抑制剂胰蛋白酶抗体以及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2347973C (en) 1999-07-20 2010-06-22 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
US7888482B2 (en) * 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
MA49886A (fr) 2017-03-16 2020-06-24 Medimmune Ltd Anticorps anti-par2 et leurs utilisations
AU2021328375A1 (en) * 2020-08-18 2023-04-13 Cephalon Llc Anti-PAR-2 antibodies and methods of use thereof

Similar Documents

Publication Publication Date Title
TWI850203B (zh) 抗體、可活化之抗體、雙特異性抗體、和雙特異性可活化之抗體、及其使用方法
JP5632744B2 (ja) ヒト神経成長因子に対する高親和性ヒト抗体
FI3740504T3 (fi) CD70-yhdistelmähoito
JP2020536109A5 (cg-RX-API-DMAC7.html)
AU2021221287B2 (en) Engineered anti-IL-2 antibodies
CA2792740A1 (en) Antibodies with ph dependent antigen binding
RU2011128332A (ru) Антитело против siglec-15
JP2011502137A5 (cg-RX-API-DMAC7.html)
AU2016369307A1 (en) Multi-specific antibody molecules having specificity for TNF-alpha, IL-17A and IL-17F
CN111944048A (zh) 抗cldn抗体及其药物组合物和检测方法
US12053530B2 (en) Plectin-1 binding antibodies and uses thereof
JP2021511024A5 (cg-RX-API-DMAC7.html)
CA3207494A1 (en) Hhla2 binding agents with novel activity
JP2009529915A5 (cg-RX-API-DMAC7.html)
EP4243827A1 (en) Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer
US20140065154A1 (en) Tlr3 binding agents
JP2022534794A5 (cg-RX-API-DMAC7.html)
CN114040776A (zh) Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途
JP2021533142A5 (cg-RX-API-DMAC7.html)
CN109071659B (zh) 人抗fgfr4抗体和索拉非尼的组合
TWI865617B (zh) 抗原結合蛋白
JP2019535716A5 (cg-RX-API-DMAC7.html)
JP2023527200A5 (cg-RX-API-DMAC7.html)
EP3882271A2 (en) Ifn-gamma-inducible regulatory t cell convertible anti-cancer (irtca) antibody and uses thereof
WO2023134787A3 (zh) 抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途